10-Q: Pharma-Bio Serv Reports Q3 Revenue Growth, Net Income Improvement

Pharma-Bio Serv, Inc. filed its Q3 2026 10-Q, reporting an increase in revenues and a significant improvement in net income compared to the prior year, alongside ongoing efforts to collect a substantial legal judgment.

Summary

• Pharma-Bio Serv, Inc. reported revenues of $2.34 million for the three months ended July 31, 2026, an increase from $1.96 million in the same period last year. For the nine-month period, revenues were $7.33 million, up from $6.85 million in the prior year.
• Net income for the three months ended July 31, 2026, was a loss of $14,219, an improvement from a loss of $204,250 in the prior year. The nine-month period showed a net income of $251,627, a significant increase from a net loss of $100,361 in the prior year.
• The company's cash and cash equivalents decreased to $1.52 million as of July 31, 2026, from $3.38 million as of October 31, 2025.
• A significant legal judgment of $6,717,431.69 was awarded to the company's subsidiaries against Romark Global Pharma, LLC, though collection efforts are ongoing with no guarantee of success.
• The company is awaiting an update on its request to extend a tax grant from PRIDCO for its Puerto Rico operations.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, with improvements in net income and revenue compared to the prior year's periods, but still facing operational challenges and a significant legal judgment.

Positives

• Revenues increased by approximately $0.4 million to $2.34 million for the three months ended July 31, 2026, compared to the same period last year.
• Revenues for the nine months ended July 31, 2026, increased by approximately $0.5 million to $7.33 million compared to the same period last year.
• Net income improved significantly, moving from a loss of $204,250 in Q3 2025 to a loss of $14,219 in Q3 2026.
• For the nine-month period, net income was $251,627 in 2026, a substantial improvement from a net loss of $100,361 in 2025.
• Selling, general and administrative expenses decreased by approximately $0.1 million for the three-month period and $0.3 million for the nine-month period compared to the prior year.
• The company has $1.44 million shares available for repurchase under its stock repurchase program.

Negatives

• The company incurred a net loss of $14,219 for the three months ended July 31, 2026.
• Cash and cash equivalents decreased from $3.38 million to $1.52 million between October 31, 2025, and July 31, 2026.
• The company is actively pursuing collection of a $6.7 million judgment against Romark Global Pharma, LLC, but has been unable to identify assets for collection, and success is not guaranteed.
• The company's PRIDCO tax grant, which expired on October 31, 2024, is pending renewal, and there is no update on the status of the request.
• The company's revenues are concentrated among a few customers, with four global groups accounting for 55.8% of revenues in the nine-month period of 2026.

Risks

• Regional or global conflicts, economic sanctions, price inflation, pandemics, changes in tax laws, bio-pharmaceutical industry consolidations and relocations, and trends in managing contract resources pose current and future challenges.
• The company's future profitability and liquidity are dependent on the effect of the local and global economy, including impacts of conflicts, inflation, pandemics, tax law changes, and industry consolidations.
• The company is exposed to customer concentration risk, with significant portions of revenue and accounts receivable concentrated among a few customers.
• The company is pursuing collection of a substantial legal judgment, but there is no guarantee of a successful outcome.
• The company is awaiting an update on the extension of a key tax grant from PRIDCO, which expired in October 2024.

Future Outlook

Management believes that current working capital, operations, cash flows from operations, and collectability of receivables are sufficient to fund anticipated expenses and contractual commitments for beyond the next twelve months. However, uncertainties related to the global economy, competition, industry trends, and regulatory matters may adversely affect future performance.

Management Comments

• Management believes that based on the current level of working capital, operations and cash flows from operations, and the collectability of high-quality customer receivables are sufficient to fund anticipated expenses and satisfy other possible long-term contractual commitments for and beyond the next twelve months.
• Management is not aware of any other trends or events likely to have a material adverse effect on liquidity or its financial statements, despite existing uncertainties in the consulting services industry.

Industry Context

StockSavvy.ai notes that Pharma-Bio Serv operates in the technical compliance consulting sector, serving the pharmaceutical, chemical, medical device, and biotechnology industries. This sector is characterized by local and international compliance firms, as well as larger engineering and consulting entities. The company's focus on FDA and international agency regulatory compliance is a key differentiator.

Comparison to Industry Standards

• The filing does not provide specific comparisons to industry benchmarks or named competitors.
• The company's gross profit margin for the nine-month period was 31.6%, which is a healthy margin for a consulting services firm.
• The company's revenue growth of approximately 7.3% for the nine-month period is moderate and needs to be assessed against industry growth rates, which are not provided.

Legal Proceedings

• Pharma-Bio Serv PR, Inc., Pharma Serv, Inc. and Scienza Labs, Inc. filed a breach of contract and money collection complaint against Romark Global Pharma, LLC, Romark Properties, LLC, Romark Biosciences, LLC and Romark Holdings, LLC. A judgment was entered ordering Romark to pay $6,717,431.69, but collection efforts are ongoing with no guarantee of success.
• There are currently no other proceedings threatened or pending against the company that would have a material adverse effect on its financial position or results of operations.

Stakeholder Impact

• Shareholders: The improvement in net income and revenue, along with the ongoing stock repurchase program, may be viewed positively. However, the decrease in cash and the uncertainty around the legal judgment collection could be concerns.
• Creditors: The company's working capital and stated belief in its ability to meet obligations suggest a stable outlook for creditors.
• Employees: The company's continued operations and focus on compliance consulting indicate ongoing employment opportunities.
• Customers: The company's ability to provide compliance services is critical, and the concentration of revenue among a few customers highlights the importance of maintaining these relationships.

Next Steps

• Continue pursuing collection of the legal judgment against Romark Global Pharma, LLC.
• Await status update from PRIDCO regarding the extension of the tax grant.
• Continue to operate and adapt business strategies to new opportunities and challenges in the market.
• Manage cash flow and working capital to fund anticipated expenses and contractual commitments.

Key Dates

Recommendation

The company shows signs of operational improvement with increased revenue and reduced losses, particularly in the nine-month period. However, the decrease in cash, significant customer concentration, and the unresolved substantial legal judgment collection introduce considerable risk. The pending renewal of a key tax grant also adds uncertainty. Therefore, a 'hold' recommendation is appropriate, pending further clarity on the collection of the judgment and the tax grant renewal.

Keywords

technical compliance consulting, pharmaceutical industry, biotechnology, medical devices, Puerto Rico, United States, Europe, regulatory compliance